AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Wnt Signaling Pathway Inhibitor Pipeline Insight, 2019 Report Featuring Samumed, Mereo BioPharma, OncoMed Pharmaceuticals, & PRISM BioLab - ResearchAndMarkets.com

April 9, 2019

DUBLIN--(BUSINESS WIRE)--Apr 9, 2019--The “Wnt Signaling Pathway Inhibitor -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Wnt Signaling Pathway Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Wnt Signaling Pathway Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Wnt Signaling Pathway Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • Provides a snapshot of the therapeutics pipeline activity for Wnt Signaling Pathway Inhibitor
  • Features the Wnt Signaling Pathway Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Wnt Signaling Pathway Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Wnt Signaling Pathway Inhibitor

Key Topics Covered:

1. Report Introduction

2. Wnt Signaling Pathway Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Wnt Signaling Pathway Inhibitor

4. Comparative Analysis

5. Wnt Signaling Pathway Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Wnt Signaling Pathway Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Samumed
  • Mereo BioPharma
  • OncoMed Pharmaceuticals
  • PRISM BioLab

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lqcax4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190409005621/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/09/2019 08:54 AM/DISC: 04/09/2019 08:54 AM

http://www.businesswire.com/news/home/20190409005621/en